Wang et al. demonstrated that using COX-2 inhibitor with anti-PD-1 antibody, the objective response rate at six months significantly improved in patients with metastatic melanoma and NSCLC, compared with the anti-PD-1 strategy (148). Here, PTGS2 is linked to metastatic melanoma.